• My research goals are to develop an improved understanding of abnormal regulation of malignant stem and progenitor cells in hematologic malignancies and to develop effective approaches to eliminate these cells to enhance outcomes for these cancers. In addition to being a practicing clinical Hematologist-Oncologist and Hematopoietic Cell Transplant physician, I have extensive experience in studying normal and malignant hematopoietic stem cell regulation in the translational laboratory setting.
    During my fellowship at the University of Minnesota, under the mentorship of Dr. Catherine Verfaillie and Dr. Philip McGlave, I studied mechanisms of microenvironmental regulation of normal and malignant hematopoiesis, and mechanisms of response and resistance of leukemia stem cells to therapy.
    After establishing my independent research program at City of Hope, I have continued to investigate mechanisms of regulation of normal and leukemia stem cell growth and therapeutic targeting of leukemia stem cells. My research goals are to develop an improved understanding of abnormal regulation of malignant stem and progenitor cells in hematologic malignancies and to develop effective approaches to eliminate these cells to enhance outcomes for these cancers.
    I was appointed as Director of the Division of Hematopoietic Stem Cell and Leukemia Research and co-Director of the Hematological Malignancies Program in the Comprehensive Cancer Center in 2006 to develop a basic and translational program in hematological malignancies and hematopoietic stem cells at our center.
    Since taking over this position, I have recruited and mentored an outstanding group of young faculty with a common interest in investigating mechanisms of regulation of normal stem cell growth; cellular and molecular mechanisms underlying hematopoietic cell transformation in patients with hematological malignancies; identification of critical therapeutic targets; and preclinical and clinical development of innovative, mechanism-based therapeutic interventions.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2020 Erratum: Mesenchymal Niche-Specific Expression of Cxcl12 Controls Quiescence of Treatment-Resistant Leukemia Stem Cells (Cell Stem Cell (2019) 24(5) (769–784.e6), (S1934590919300700), (10.1016/j.stem.2019.02.018))Cell Stem Cell.  26:123. 2020
    2020 Expenditures for First- A nd Second-Generation Tyrosine Kinase Inhibitors before and after Transition of Imatinib to Generic StatusJAMA Oncology2020
    2019 Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) reportCancer.  125:4033-4042. 2019
    2019 Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemiaCancer.  125:2570-2578. 2019
    2019 Mapping Distinct Bone Marrow Niche Populations and Their Differentiation PathsCell Reports.  28:302-311.e5. 2019
    2019 Mesenchymal Niche-Specific Expression of Cxcl12 Controls Quiescence of Treatment-Resistant Leukemia Stem CellsCell Stem Cell.  24:769-784.e6. 2019
    2019 PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemiaNature Genetics.  51:296-307. 2019
    2019 SIRT1 regulates metabolism and leukemogenic potential in CML stem cellsJournal of Clinical Investigation.  129:2685-2701. 2019
    2019 TARGETING LEUKEMIA STEM CELL RESISTANCE IN CHRONIC MYELOGENOUS LEUKEMIATransactions- American Clinical and Climatological Association.  130:246-254. 2019
    2018 A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockageNature Communications.  9. 2018
    2018 Assessment of Late Mortality Risk After Allogeneic Blood or Marrow Transplantation Performed in ChildhoodJAMA Oncology.  4. 2018
    2018 Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage (Nature Communications (2018) DOI: 10.1038/s41467-018-03441-3)Nature Communications.  9. 2018
    2018 Late mortality after allogeneic blood or marrow transplantation in childhood for leukemia: a report from the Blood or Marrow Transplant Survivor Study-2Leukemia.  32:2706-2709. 2018
    2018 Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplantBone Marrow Transplantation.  53:1345-1348. 2018
    2018 SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 FunctionCell Stem Cell.  23:355-369.e9. 2018
    2018 Chronic myeloid leukemia, version 1.2019Journal of the National Comprehensive Cancer Network.  16:1108-1135. 2018
    2018 Late mortality after autologous blood or marrow transplantation in childhood: A Blood or Marrow Transplant Survivor Study-2 reportBlood.  131:2720-2729. 2018
    2018 Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor CellsCell Reports.  23:3127-3136. 2018
    2018 Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemiaNature Medicine.  24:450-462. 2018
    2018 JMJD1B Demethylates H4R3me2s and H3K9me2 to Facilitate Gene Expression for Development of Hematopoietic Stem and Progenitor CellsCell Reports.  23:389-403. 2018
    2018 hsa-mir183/EGR1–mediated regulation of E2F1 is required for CML stem/progenitor cell survivalBlood.  131:1532-1544. 2018
    2018 Autophagic flux blockage by accumulation of weakly basic tenovins leads to elimination of B-Raf mutant tumour cells that survive vemurafenibPLoS ONE.  13. 2018
    2018 Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretionLeukemia.  32:575-587. 2018
    2018 Congenital Hypothyroid Screening in Term Neonates Using Cord Blood TSHJournal of Neonatology.  32:12-14. 2018
    2018 Congenital hypothyroidism screening in term neonates using umbilical cord blood TSH valuesIndian Journal of Endocrinology and Metabolism.  22:277-279. 2018
    2018 Preservation of quiescent chronic myelogenous leukemia stem cells by the bone marrow microenvironmentAdvances in Experimental Medicine and Biology.  1100:97-110. 2018
    2017 Novel approaches to therapy in CMLHematology online (ASH).  2017:115-120. 2017
    2017 The T-ALL related gene BCL11B regulates the initial stages of human T-cell differentiationLeukemia.  31:2503-2514. 2017
    2017 Myeloproliferative neoplasms, version 2.2018 featured Updates to the NCCN guidelinesJournal of the National Comprehensive Cancer Network.  15:1193-1207. 2017
    2017 Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cellsJournal of Clinical Investigation.  127:2392-2406. 2017
    2017 Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphomaJournal of Clinical Oncology.  35:1598-1605. 2017
    2017 Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKIBlood.  129:1008-1020. 2017
    2017 Autologous hematopoietic stem cell transplantation in lymphoma patients is associated with a decrease in the double strand break repair capacity of peripheral blood lymphocytesPLoS ONE.  12. 2017
    2017 High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in AdultsJournal of Clinical Oncology.  35:394-401. 2017
    2017 Correction: In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.PLoS ONE.  12:e0172640. 2017
    2017 Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemiaOncotarget.  8:10809-10821. 2017
    2017 Hoxa9 and Hoxa10 induce CML myeloid blast crisis development through activation of Myb expressionOncotarget.  8:98853-98864. 2017
    2017 Impact of chromosomal rearrangement upon DNA methylation patterns in leukemiaOpen Medicine.  12:76-85. 2017
    2016 Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cellsBlood.  128:2671-2682. 2016
    2016 In vitro pre-clinical validation of suicide gene modified anti-CD33 redirected chimeric antigen receptor T-cells for acute myeloid leukemiaPLoS ONE.  11. 2016
    2016 Myeloproliferative neoplasms, version 2.2017: Clinical Practice Guidelines in oncologyJournal of the National Comprehensive Cancer Network.  14:1572-1611. 2016
    2016 Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemiaNature Communications.  7. 2016
    2016 Increased urinary frequency due to P. falciparum infection - A case reportJournal of Clinical and Diagnostic Research.  10:SL02. 2016
    2016 Leukemoid Reaction due to P. falciparum InfectionIndian Journal of Pediatrics.  83:1501-1502. 2016
    2016 Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cellsScience Translational Medicine.  8. 2016
    2016 Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemiaScientific Reports.  6. 2016
    2016 Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cellsJournal of Clinical Investigation.  126:975-991. 2016
    2016 Haemophagocytic syndrome in a four year old male child with plasmodium vivax infectionJournal of Nepal Paediatric Society.  36:193-195. 2016
    2016 Neonatal leukemoid reaction - a diagnostic dilemmaJournal of Nepal Paediatric Society.  36:298-299. 2016
    2015 HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 AcetylationCell Stem Cell.  17:597-610. 2015
    2015 Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemiaProceedings of the National Academy of Sciences.  112:10786-10791. 2015
    2015 In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer DrugsMayo Clinic Proceedings.  90:996-1000. 2015
    2015 Role of SIRT1 in the growth and regulation of normal hematopoietic and leukemia stem cellsCurrent opinion in hematology.  22:324-329. 2015
    2015 Osteoblast ablation reduces normal long-term hematopoietic stem cell self-renewal but accelerates leukemia developmentBlood.  125:2678-2688. 2015
    2015 MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitorsBlood.  125:1302-1313. 2015
    2015 Influence of Bone Marrow Microenvironment on Leukemic Stem Cells: Breaking Up an Intimate RelationshipAdvances in Cancer Research.  127:227-252. 2015
    2014 Pushing the limits: Defeating leukemia stem cells by depleting telomeraseCell Stem Cell.  15:673-675. 2014
    2014 Leukemia cells make ruthless competitorsBlood.  124:2900-2901. 2014
    2014 JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivoBlood.  124:1492-1501. 2014
    2014 Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cellsBlood.  123:2826-2837. 2014
    2014 Granulocytes affect double-strand break repair assays in primary human lymphocytesPLoS ONE.  9. 2014
    2014 Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunityBlood.  123:15-25. 2014
    2014 ATRA-Induced Cellular Differentiation and CD38 Expression Inhibits Acquisition of BCR-ABL Mutations for CML Acquired ResistancePLoS Genetics.  10. 2014
    2014 Iron chelators induce autophagic cell death in multiple myeloma cellsLeukemia Research.  38:988-996. 2014
    2014 SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cellsCell Stem Cell.  15:431-446. 2014
    2013 T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemiaBlood.  122:3138-3148. 2013
    2013 PP2A-activating drugs selectively eradicate tki-resistant chronic myeloid leukemic stem cellsJournal of Clinical Investigation.  123:4144-4157. 2013
    2013 Roles of SIRT1 in leukemogenesisCurrent opinion in hematology.  20:308-313. 2013
    2013 Stem cell therapy: A clinical trial of strokeClinical Neurology and Neurosurgery.  115:1003-1008. 2013
    2013 Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cellsBlood.  121:4175-4183. 2013
    2013 Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signalingBlood.  121:1824-1838. 2013
    2013 A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemiaEMBO Molecular Medicine.  5:353-365. 2013
    2013 TLR9-mediated siRNA delivery for Targeting of normal and malignant human hematopoietic cells in vivoBlood.  121:1304-1315. 2013
    2013 SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cellsOncogene.  32:589-598. 2013
    2013 Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferationBlood.  122:3335-3339. 2013
    2013 The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agentsBlood.  122:1900-1913. 2013
    2013 The controversial role of Sirtuins in tumorigenesis-SIRT7 joins the debateCell Research.  23:10-12. 2013
    2012 Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylationLeukemia & Lymphoma.  53:2474-2478. 2012
    2012 Hereditary leukemia due to rare RUNX1c splice variant (L472X) presents with eczematous phenotype.International Journal of Clinical Medicine.  3. 2012
    2012 Intrathoracic airway obstruction and gastroesophageal reflux: A canine modelPediatric Pulmonology.  47:1097-1102. 2012
    2012 Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxisLeukemia Research.  36:1152-1156. 2012
    2012 Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitorsLeukemia Research.  36:966-973. 2012
    2012 Chronic myelogenous leukemia stem and progenitor cells demonstrate chromosomal instability related to repeated breakage-fusion-bridge cycles mediated by increased nonhomologous end joiningBlood.  119:6187-6197. 2012
    2012 Setbp1 promotes the self-renewal of murine myeloid progenitors via activation of Hoxa9 and Hoxa10Blood.  119:6099-6108. 2012
    2012 Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous LeukemiaCancer Cell.  21:577-592. 2012
    2012 Genetic susceptibility to therapy-related leukemia after Hodgkin lymphoma or non-Hodgkin lymphoma: Role of drug metabolism, apoptosis and DNA repairBlood Cancer Journal.  2. 2012
    2012 Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesisBlood.  119:1904-1914. 2012
    2012 Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with ImatinibCancer Cell.  21:266-281. 2012
    2012 Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survivalBlood.  119:1501-1510. 2012
    2012 Overcoming CML acquired resistance by specific inhibition of Aurora a kinase in the KCL-22 cell modelCarcinogenesis.  33:285-293. 2012
    2012 Indirubin derivatives induce apoptosis of chronic myelogenous leukemia cells involving inhibition of Stat5 signalingMolecular Oncology.  6:276-283. 2012
    2011 Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatmentBlood.  118:5565-5572. 2011
    2011 Altered Hematopoietic Cell Gene Expression Precedes Development of Therapy-Related Myelodysplasia/Acute Myeloid Leukemia and Identifies Patients at RiskCancer Cell.  20:591-605. 2011
    2011 Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic miceBlood.  118:2159-2169. 2011
    2011 Acritical role for SHP2 in STAT5 activation and growth factor-mediated proliferation, survival, and differentiation of human CD34+ cellsBlood.  118:1504-1515. 2011
    2011 Stem cell quiescenceClinical Cancer Research.  17:4936-4941. 2011
    2011 The LRF transcription factor regulates mature B cell development and the germinal center response in miceJournal of Clinical Investigation.  121:2583-2598. 2011
    2011 NMR-based metabolomic analysis of the molecular pathogenesis of therapy-related myelodysplasia/acute myeloid leukemiaJournal of Proteome Research.  10:2873-2881. 2011
    2011 Treatment-related myelodysplastic syndrome: Molecular characteristics and therapyCurrent opinion in hematology.  18:77-82. 2011
    2011 Inhibition of Grb2 expression demonstrates an important role in BCR-ABL-mediated MAPK activation and transformation of primary human hematopoietic cellsLeukemia.  25:305-312. 2011
    2011 Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemiaLeukemia.  25:463-472. 2011
    2010 Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib MesylateCancer Cell.  17:427-442. 2010
    2010 Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cellsBlood.  115:2241-2250. 2010
    2010 miR-328 Functions as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic BlastsCell.  140:652-665. 2010
    2010 BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemiaJournal of Biological Chemistry.  285:5085-5096. 2010
    2010 Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapyLeukemia.  24:1299-1301. 2010
    2010 Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitorsLeukemia.  24:779-787. 2010
    2009 Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphomaJournal of Clinical Oncology.  27:791-798. 2009
    2009 Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cellsExperimental Hematology.  37:206-214. 2009
    2008 Effects of dasatinib on Src kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cellsCancer Research.  68:9624-9633. 2008
    2008 Excellent supervisionNew Scientist.  200:19. 2008
    2008 Gene expression pattern in myelodyplasia underline the role of apoptosis and differentiation in disease initiation and progressionTranslational Oncogenomics.  2008:137-149. 2008
    2008 The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph - acute lymphoblastic leukemia cellsBlood.  111:5093-5100. 2008
    2008 Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606Blood.  111:2329-2338. 2008
    2008 CREB is a critical regulator of normal hematopoiesis and leukemogenesisBlood.  111:1182-1192. 2008
    2008 Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitorsLeukemia.  22:748-755. 2008
    2007 Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantationTransfusion.  47:2207-2216. 2007
    2007 Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intoleranceBlood.  110:3540-3546. 2007
    2007 Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndromeBone Marrow Transplantation.  40:843-850. 2007
    2007 Kangaroo Mother Care (KMC) in LBW infants - A western Rajasthan experienceIndian Journal of Pediatrics.  74:747-749. 2007
    2007 BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemiaCancer Research.  67:7045-7053. 2007
    2007 Monitoring repair of DNA damage in cell lines and human peripheral blood mononuclear cellsAnalytical Biochemistry.  365:246-259. 2007
    2007 Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cellsBlood.  109:5411-5421. 2007
    2007 Low birth weight and insulin resistance in mid and late childhoodIndian Pediatrics.  44:177-184. 2007
    2007 The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemiaBlood.  109:1782-1789. 2007
    2007 Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatmentCancer Research.  67:1113-1120. 2007
    2007 Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic cloneLeukemia Research.  31:261-265. 2007
    2007 Rheumatoid neuropathyIndian Journal of Rheumatology.  2:45-46. 2007
    2006 Escaping inhibition by self-mutationBlood.  108:7. 2006
    2006 Soil solarization for managing weeds in brinjal (Solanum melongena) nurseryIndian Journal of Agricultural Sciences.  76:129-131. 2006
    2005 Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphomaJournal of Clinical Oncology.  23:6699-6711. 2005
    2005 Pediatric HIV infection/AIDS in Agra [2]Indian Pediatrics.  42:953-954. 2005
    2005 Expression of DLK1 in hematopoietic cells results in inhibition of differentiation and proliferationOncogene.  24:4472-4476. 2005
    2005 Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host diseaseBiology of Blood and Marrow Transplantation.  11:307-313. 2005
    2005 Detection of BCR-ABL kinase mutations in CD34 + cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatmentBlood.  105:2093-2098. 2005
    2005 Keratomalacia in a neonate secondary to maternal vitamin A deficiencyIndian Journal of Pediatrics.  72:881-882. 2005
    2005 Nonproliferating CML CD34+ progenitor are resistant to apoptosis induced by a wide range of proapoptotic stimuliLeukemia.  19:1034-1041. 2005
    2005 Reproducibility, fidelity, and discriminant validity of mRNA amplification for microarray analysis from primary hematopoietic cellsJournal of Molecular Diagnostics.  7:48-56. 2005
    2004 Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: Results from the Bone Marrow Transplant Survivor StudyBlood.  104:1898-1906. 2004
    2004 Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitorsCancer Research.  64:5322-5331. 2004
    2004 Autologous hematopoietic cell transplantation for chronic myelogenous leukemiaHematology/Oncology Clinics of North America.  18:715-732. 2004
    2004 BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cellsBlood.  103:3167-3174. 2004
    2004 Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cellsLeukemia & Lymphoma.  45:237-245. 2004
    2003 Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failedBiology of Blood and Marrow Transplantation.  9:649-656. 2003
    2003 Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed.Biology of Blood and Marrow Transplantation.  9:649-656. 2003
    2003 Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatmentBlood.  101:4701-4707. 2003
    2003 A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: Impact of cytogenetic characteristics on transplantation outcomeBiology of Blood and Marrow Transplantation.  9:766-771. 2003
    2002 Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferationBlood.  99:3792-3800. 2002
    2002 Contact with fibronectin enhances preservation of normal but not chronic myelogenous leukemia primitive hematopoietic progenitorsExperimental Hematology.  30:324-332. 2002
    2001 Abnormal growth factor modulation of β1-integrin-mediated adhesion in chronic myelogenous leukaemia haematopoietic progenitorsBritish Journal of Haematology.  115:845-853. 2001
    2001 Solid cancers after bone marrow transplantationJournal of Clinical Oncology.  19:464-471. 2001
    2000 Amifostine (ETHOYL) in Combination with topotecan and ARA-C for patients with poor risk myelodysplasia (MDS) and secondary acute myelogenous leukemiaBlood.  96. 2000
    2000 Chronic myelogenous leukemia primitive hematopoietic progenitors demonstrate increased sensitivity to growth factor-induced proliferation and maturationExperimental Hematology.  28:1401-1412. 2000
    2000 Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: An assessment of risk factorsBlood.  95:1588-1593. 2000
    2000 Autologous Stem-Cell Transplantation for Poor-Risk and Relapsed Intermediate- and High-Grade Non-Hodgkin's LymphomaClinical lymphoma.  1:46-54. 2000
    2000 Effects of Allogeneic Bone Marrow Transplantation on Recipient Bone Mineral Density: A Prospective StudyBiology of Blood and Marrow Transplantation.  6:344-351. 2000
    2000 Effects of allogeneic bone marrow transplantation on recipient bone mineral density: A prospective study.Biology of Blood and Marrow Transplantation.  6:344-351. 2000
    1999 Role of abnormal integrin-cytoskeletal interactions in impaired β1 integrin function in chronic myelogenous leukemia hematopoietic progenitorsExperimental Hematology.  27:1384-1396. 1999
    1999 Recombinant human thrombopoietin in combination with granulocyte colony- stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapyBlood.  93:2798-2806. 1999
    1999 High-dose chemo/radiotherapy and autologous bone marrow or stem cell transplantation for poor-risk advanced-stage Hodgkin's disease during first partial or complete remissionBiology of Blood and Marrow Transplantation.  5:292-298. 1999
    1999 Stromal extracellular matrix components as growth regulators for human hematopoietic progenitorsHematology.  4:321-333. 1999
    1999 The Hematopoietic Microenvironment: Stromal Extracellular Matrix Components As Growth Regulators For Human Hematopoietic Progenitors.Hematology.  4:321-333. 1999
    1998 Comparative analysis of autografting in chronic myelogenous leukemia: Effects of priming regimen and marrow or blood origin of stem cellsBlood.  92:1820-1831. 1998
    1998 Inhibition of BCR-ABL expression with antisense oligodeoxynucleotides restores β1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitorsBlood.  91:3414-3422. 1998
    1998 Autologous transplantation for the treatment of chronic myelogenous leukemiaHematology/Oncology Clinics of North America.  12:151-172. 1998
    1998 Interferon-α restores β1-integrin-dependent, collagen-mediated platelet aggregation in a patient with chronic myelogenous leukemiaJournal of Laboratory and Clinical Medicine.  131:163-169. 1998
    1998 The effect of interferon-α on beta-1 integrin mediated adhesion and growth regulation in chronic myelogenous leukemiaLeukemia & Lymphoma.  28:241-254. 1998
    1998 Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores β1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitorsLeukemia.  12:1708-1717. 1998
    1997 Abnormal pi integrin function in cml progenitors is related to enhanced receptor attachment to the cytoskeletonExperimental Hematology.  25:757. 1997
    1997 Defective progenitor/stroma interactions in the pathogenesis of chronic myeloid leukemiaExperimental Hematology.  25:874. 1997
    1997 A clinically suitable ex vivo expansion culture system for LTC-IC and CFC using stroma-conditioned mediumExperimental Hematology.  25:980-991. 1997
    1997 Autologous transplantation therapy for chronic myelogenous leukemiaBlood.  89:2623-2634. 1997
    1997 Autologous stem cell transplantation for the treatment of chronic myelogenous leukemia.Cancer Treatment and Research.  77:357-374. 1997
    1997 Integrin-mediated regulation of hematopoiesis: Do bcr/abl-lnduced defects in integrin function underlie the abnormal circulation and proliferation of cml progenitors?Acta Haematologica.  97:40-52. 1997
    1997 Pathophysiology of CML: Do defects in integrin function contribute to the premature circulation and massive expansion of the BCR/ABL positive clone?Journal of Laboratory and Clinical Medicine.  129:584-591. 1997
    1996 CML progenitor adhesion and adhesion-mediated proliferation inhibition is restored by tyrphostin ag957, a protein tyrosine kinase inhibitor with activity against the BCR-ABL kinaseExperimental Hematology.  24:1131. 1996
    1996 BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patientsBlood.  87:4770-4779. 1996
    1996 Cyclophosphamide/GM-CSF priming in autotransplant therapy for CMLBone Marrow Transplantation.  17. 1996
    1996 Interferon-α restores normal β1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemiaBlood.  87:3883-3891. 1996
    1995 Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: Role of malignant stromal macrophagesBlood.  85:3636-3645. 1995
    1995 Autografting for chronic myelogenous leukemia.Current opinion in hematology.  2:436-443. 1995
    1995 T lymphocytes cultured from chronic myelogenous leukemia bone marrow suppress autologous hematopoietic progenitorsLeukemia.  9:1006-1012. 1995
    1995 Treatment of marrow stroma with interferon-α restores normal β1 integrin-dependent adhesion of chronic myelogenous leukemia hematopoietic progenitors: Role of MIP-1αJournal of Clinical Investigation.  96:931-939. 1995
    1994 Interferon-α restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired β1 integrin receptor functionJournal of Clinical Investigation.  94:384-391. 1994
    1994 Role of bone marrow matrix in normal and abnormal hematopoiesisCritical Reviews in Oncology/Hematology.  16:201-224. 1994
    1990 Immunologic and immunogenetic studies in rheumatic fever and rheumatic heart diseaseIndian Journal of Pediatrics.  57:693-700. 1990
    1990 Fluorides in urolithiasis - A preliminary surveyIndian Journal of Urology.  7:22-24. 1990
    1989 Prenatal diagnosis of Tay-Sachs disease.Indian Pediatrics.  26:1052-1053. 1989
    1989 Citrullinemia: early diagnosis & successful management of an otherwise lethal disorder.Indian Pediatrics.  26:589-592. 1989
    1989 Lymphocyte subsets in acute rheumatic fever and rheumatic heart diseaseClinical Cardiology.  12:34-38. 1989


    Year Title Altmetric
    2018 Chronic Myeloid Leukemia.  1055-1070. 2018
    2016 Hematopoietic Stem Cell Transplantation for Chronic Myeloid Leukemia.  545-556. 2016
    2016 Subsequent Malignant Neoplasms After Hematopoietic Cell Transplantation.  1275-1289. 2016
    2015 Transplantation-related malignancies 2015
    2014 Models to Study Chronic Myeloid Leukemia Cancer Stem Cells.  119-131. 2014
    2009 Allogeneic and Autologous Transplantation for Chronic Myeloid Leukemia.  734-750. 2009
    2009 Secondary Malignancies after Hematopoietic Cell Transplantation.  1638-1652. 2009
    2000 Cell signaling by adhesion receptors in normal and leukemic hematopoiesis.  125-136. 2000

    Research Overview

  • Hematopoietic stem cells
    Chronic myelogenous leukemia
    Myelodysplastic syndrome
    Acute Myeloid Leukemia
  • Principal Investigator On

  • Microenvironmental Regulation Of Leukemia Stem Cells  awarded by National Cancer Institute/NIH/DHHS 2019 - 2024
  • Private Grant  awarded by ASTEX PHARMACEUTICALS 2019 - 2024
  • ACS Institutional Research Grant  awarded by American Cancer Society, Inc. 2019 - 2021
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2019 - 2021
  • Comprehensive Cancer Center Core Support Grant - Administrative Supplements to Strengthen NCI-Supported Community Outreach Capacity through Community Health Educators (CHEs)  awarded by National Cancer Institute/NIH/DHHS 2019 - 2021
  • Comprehensive Cancer Center Core Support Grant - Developmental Funds  awarded by National Cancer Institute/NIH/DHHS 2019 - 2021
  • Resistance Of Leukemia Stem Cells To TKI  awarded by American Society of Hematology 2019 - 2020
  • Research Training Program in Basic and Translational Oncology  awarded by National Cancer Institute/NIH/DHHS 2017 - 2019
  • Private Grant  awarded by AMGEN, INC. 2018 - 2019
  • Microenvironmental Regulation of Leukemia Stem Cells  awarded by National Cancer Institute/NIH/DHHS 2015 - 2019
  • Resistance of CML Stem Cells to Imatinib (Gleevec)  awarded by National Cancer Institute/NIH/DHHS 2015 - 2019
  • Molecular Pathogenesis of Therapy-Related Myelodysplasia  awarded by V FOUNDATION FOR CANCER RESEARCH 2015 - 2017
  • Targeting FLT3 Mutated AML Stem Cells Using Sirtuin Inhibition  awarded by Leukemia and Lymphoma Society 2014 - 2017
  • City of Hope Lymphoma SPORE (Core C)  awarded by BECKMAN RESEARCH INSTITUTE (CITY OF HOPE) 2015 - 2016
  • City of Hope Lymphoma SPORE (Project 2)  awarded by City of Hope 2015 - 2016
  • Targeting the Leukemia Stem Cell in CML  awarded by SAMUEL WAXMAN CANCER RESEARCH FOUNDATION 2015 - 2016
  • Investigator On

  • Private Grant  awarded by KARTOS THERAPEUTICS INC. 2019 - 2024
  • BMT Survivor Study-2 (BMTSS-2)  awarded by National Cancer Institute/NIH/DHHS 2019 - 2024
  • City of Hope Lymphoma SPORE  awarded by BECKMAN RESEARCH INSTITUTE (CITY OF HOPE) 2018 - 2023
  • Private Grant  awarded by AMGEN, INC. 2019 - 2023
  • Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease, BMT CTN PROTOCOL #1507  awarded by National Marrow Donor Program 2017 - 2023
  • Private Grant  awarded by ABBVIE INC 2018 - 2023
  • A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML  awarded by National Marrow Donor Program 2017 - 2022
  • Role of Oncometabolite L-2 Hydroxyglutarate in Reprogramming Renal Cell Carcinoma Metabolism  awarded by National Cancer Institute/NIH/DHHS 2018 - 2022
  • Private Grant  awarded by FATE THERAPEUTICS, INC. 2017 - 2021
  • Private Grant  awarded by JUNO THERAPEUTICS 2018 - 2021
  • Private Grant  awarded by AMGEN, INC. 2018 - 2019
  • BMT CTN 1302- Multicenter Phase II, Double Blinded, Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma  awarded by National Marrow Donor Program 2017 - 2019
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2017 - 2019
  • Comprehensive Cancer Center Core Support Grant - Adiministrative Core  awarded by National Cancer Institute/NIH/DHHS 2017 - 2019
  • Private Grant  awarded by FATE THERAPEUTICS, INC. 2016 - 2018
  • Private Grant  awarded by JUNO THERAPEUTICS 2016 - 2018
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Comprehensive Cancer Center Core Support Grant - Administrative Core  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Active - Senior Leadership - Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Education And Training

  • Doctor of Medicine in Internal Medicine Residency Program, All India Institute of Medical Sciences 1988
  • Bachelor of Medicine & Surgery (MBBS), All India Institute of Medical Sciences 1984
  • All India Institue of Medical Science, Internship 1984
  • All India Institue of Medical Science, Residency 1989
  • All India Institue of Medical Science, Residency 1988
  • University of Minnesota, Postdoctoral Fellowship 1994
  • Full Name

  • Ravi Bhatia